Wei, M.; Han, W.; Zhang, J.; Liu, Y.; Yu, H.; Li, J.; Wang, W.
Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (Escherichia coli) in Healthy Chinese Women Aged 18–45 Years: A Phase 1 Clinical Trial. Vaccines 2025, 13, 511.
https://doi.org/10.3390/vaccines13050511
AMA Style
Wei M, Han W, Zhang J, Liu Y, Yu H, Li J, Wang W.
Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (Escherichia coli) in Healthy Chinese Women Aged 18–45 Years: A Phase 1 Clinical Trial. Vaccines. 2025; 13(5):511.
https://doi.org/10.3390/vaccines13050511
Chicago/Turabian Style
Wei, Mingwei, Weiwei Han, Jing Zhang, Yongjiang Liu, Hongyang Yu, Jingxin Li, and Wenjuan Wang.
2025. "Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (Escherichia coli) in Healthy Chinese Women Aged 18–45 Years: A Phase 1 Clinical Trial" Vaccines 13, no. 5: 511.
https://doi.org/10.3390/vaccines13050511
APA Style
Wei, M., Han, W., Zhang, J., Liu, Y., Yu, H., Li, J., & Wang, W.
(2025). Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (Escherichia coli) in Healthy Chinese Women Aged 18–45 Years: A Phase 1 Clinical Trial. Vaccines, 13(5), 511.
https://doi.org/10.3390/vaccines13050511
